Galera Therapeutics (GRTX) Eliminates COO Position

On June 4, 2024, Galera Therapeutics (NASDAQ: GRTX) notified Robert A. Beardsley, Ph.D., the Company’s Chief Operating Officer, that his position is being eliminated in order to save costs as the Company continues to undertake a comprehensive review of strategic alternatives for both the Company and its portfolio of dismutase mimetics. In connection with Dr. Beardsley’s separation from the Company, the Company expects to enter into a separation agreement with Dr. Beardsley pursuant to which Dr. Beardsley is expected to be eligible to receive the severance payments and benefits under his employment agreement with the Company, in exchange for executing a general release of claims in favor of the Company. In addition, the Company expects to engage Dr. Beardsley for consulting services on an hourly basis at a rate of on or around US$400 per hour.

You May Also Be Interested In

• TELA Bio names Heather Getz as chief executive officer
• ZEO ScientifiX plans three-day regenerative medicine event in October
• CMS grants NTAP status for Abeona's ZEVASKYN skin therapy